PROFESSOR LARS LIDGREN
The Company started as a research company in the early 2000s by Professor Lars Lidgren, with the vision of developing a synthetic product that could replace autograft and improve the quality of life for patients suffering from bone diseases.
The randomized controlled trial CERTiFy ”Autologous Iliac Bone Graft Compared with Biphasic Hydroxyapatite and Calcium Sulfate Cement for the Treatment of Bone Defects in Tibial Plateau Fractures” is published by Hofman et al in Journal of Bone and; Joint Surgery (American). The study confirms that patient reported outcomes and bone remodeling for CERAMENT BONE VOID FILLER are as good as autograft, but with less post-operative pain and blood loss.
The largest analysis of Health Economic Data for a bone substitute is presented at EBJIS. The analysis included 25000 patients and compared the clinical and financial results of Nuffield Orthopedic Hospital’s care model including antibiotic eluting CERAMENT with the care provided at other hospitals in England.
Ferguson et al. publish the paper “Radiographic and Histological Analysis of a Synthetic Bone Graft Substitute Eluting Gentamicin in the Treatment of Chronic Osteomyelitis” in the Journal of Bone and Joint infection. The study includes clinical biopsies and histology confirming bone remodeling of CERAMENT G in patients.
The distribution agreement with Zimmer Biomet ends in May.
CERTiFy study demonstrates CERAMENT®|BONE VOID FILLER is non-inferior to autograft in treating tibia plateau fracture defects
BONESUPPORT sets up distribution network in USA
CERAMENT®|G approved by Health Canada
Product offering expanded by collaboration with Collagen Matrix Inc
Emil Billbäck appointed as CEO
BONESUPPORT HOLDING AB listed at NASDAQ Stockholm
FORTIFY study initiated for CERAMENT®|G*
CERAMENT® V second generation launched with CERAMENT® | Delivery System and all components sterile
FDA approval to initiate pivotal IDE clinical study of CERAMENT®|G* in USA
Paper in Nature Scientific Reports demonstrates the potential of the CERAMENT® drug-eluting platform. Publication entitled ’A Biphasic Calcium Sulphate Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone’ (Raina, D et al).
Publication in The Bone and Joint Journal demonstrates the utility of CERAMENT®|G in the management of chronic osteomyelitis. Paper entitled ’Single-stage treatment of chronic osteomyelitis with a new absorbable gentamicin-loaded, calcium sulphate/hydroxyapatite biocomposite – A prospective series of 100 cases’ (McNally et al, The Bone and Joint Journal, 2016, Vol. 98-B, No. 9, p1289-96).
Richard Davies appointed as CEO
FY 2016 sales of SEK 105m (70% YoY growth)
CE-mark for CERAMENT® V* the first vancomycin antibiotic eluting injectable ceramic bone graft substitute
CERAMENT®|BONE VOID FILLER and CERAMENT®|G* launched with new CERAMENT®|Delivery System
PMA device pathway for CERAMENT®|G confirmed by FDA in the US
CE-mark for CERAMENT®|G*, the first antibiotic eluting injectable ceramic bone graft substitute
Distribution agreement with Biomet Inc for USA for CERAMENT®|BONE VOID FILLER
CE-mark for CERAMENT®|BONE VOID FILLER
BONESUPPORT was founded at the beginning of 2000 as a research company with a mission to design and develop a synthetic bone graft substitute that could replace autograft.
*CERAMENT G and CERAMENT V are only available outside the United States and have not been approved or cleared for marketing by the United States Food & Drug Administration